Trending News

Boston waterfront
#AI / data analytics / healthtech / informatics #Lab automation #Lab technology #SLAS2024

SLAS2024: Day One Highlights

Opening keynote Following a change to the schedule, Juliet Williams of Kymera Therapeutics launched the event with a popular keynote talk ‘Solving Big Problems with Small Molecule Degraders’. Williams discussed the advantages of the company’s ‘disease agnostic’ small molecule degraders, and its success so far in translating results… Read More

#News #Trending News

RNA
#Business #FDA #mRNA #Oncology #Strand Therapeutics

Strand Therapeutics cuts workforce by 18%

Strand Therapeutics has announced an 18% cut to its workforce, just days after the US Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application to initiate a first-in-human trial of STX-001 for solid tumours. On LinkedIn the company said: “This week, Strand has made the difficult strategic… Read More

#Business & Investment #News #Trending News

Child with hearing aids
#Akouos #Eli Lilly #Gene mutation #Gene therapy #Hearing Loss #Phase II trial

Gene therapy cures genetic hearing loss

In the first case of its kind, gene therapy has restored hearing in a patient in the United States. Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 Phase I/II study participant. AK-OTOF is a gene… Read More

#News #Trending News

Patient using a mammography machine
#Breast cancer #Cancer research #Clinical trial design #Clinical trials #Oncology #Phase II trial #Phesi

Breast cancer most researched disease area for third year running

Breast cancer was the most studied disease in 2023 for the third consecutive year, followed by solid tumours, stroke, Covid-19 and prostate cancer. The analysis of 65,749 recruiting clinical trials was conducted by data analytics company Phesi, as part of an annual global analysis of clinical… Read More

#Cancer Research #News #Trending News

UK
#Advanced Therapies #BioIndustry Association #Cell and gene therapy #Cell and Gene Therapy Catapult #UK

UK maintains dominant global position in cell and gene therapy

The UK is cementing its position as a global leader in cell and gene therapy (CGT), according to a new report released today by the UK BioIndustry Association (BIA), in collaboration with Citeline. The report reveals a robust sector with significant investment, the highest number of… Read More

#News #Trending News

Covid-19
#Covid variants #Covid-19 #Immunity #Omicron #University College London #University of Glasgow

Revealed: How Covid-19 variants stay ahead of immune defences

Recent SARS-CoV-2 variants such as BA.4 and BA.5 developed abilities missing from the first Omicron variants that allowed them to overcome humans’ innate immunity, according to research from University College London (UCL). The study examined viral evolution in eight Omicron variants to better understand how the… Read More

#News #Trending News

Traumatic brain injury
#Brain injury #Neuroscience #Plant-based #Psychiatry #PTSD #Stanford University

Plant-based psychoactive drug treats traumatic brain injury

New research has found that plant-based psychoactive drug ibogaine improved depression, anxiety and functioning among veterans with traumatic brain injuries (TBI). TBI from head trauma or blast explosions are a leading cause of post-traumatic stress disorder (PTSD), anxiety, depression and suicide among veterans. Stanford… Read More

#News #Trending News

Patient receiving a vaccine
#Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #Long Covid

Covid-19 vaccines found to protect against long Covid

A study has revealed that Covid-19 vaccines are effective in preventing long Covid, but the BioNTech/Pfizer vaccine provided better protection than ChAdOx1, developed by Oxford University/AstraZeneca. A research team at NDORMS (Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences), University of Oxford has found that vaccination… Read More

#News #Trending News

Market growth 2024
#Biotech #Funding #GlobalData #Investment #Market reporting

Biotech funding recovery predicted for 2024

The biotech market is heading to recovery in 2024, following a marked downturn in investment in 2022 and 2023, according to healthcare industry professionals. A GlobalData survey ‘The State of the Biopharmaceutical Industry 2024’ found that more than 40% of the healthcare industry professionals surveyed globally expressed an optimistic or… Read More

#Business & Investment #News #Trending News

#Biopharmaceuticals #Clarivate #Drug development #Drug discovery #Market reporting

Thirteen potential blockbuster drugs to watch in 2024

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. They include therapeutics for conditions including breast cancer, haemophilia A, sickle cell disease, Crohn’s disease, ulcerative colitis, respiratory syncytial virus (RSV) and multiple myeloma, among others. The predictions were… Read More

#News #Trending News #Trends & Analysis

Petri dish used for bacterial research
#AMR #Antibiotic resistance #Antibiotics #Harvard Medical School #Roche

Excitement over new antibiotics that can kill drug-resistant bacteria

A novel antibiotic class targeting a major global pathogen and threat to human health has been discovered by scientists from Roche and Harvard University (Cambridge, MA, US). In two studies published in Nature, the authors demonstrate that the new class of drug candidates can effectively target… Read More

#News #Trending News

MRSA
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Artificial intelligence (AI) #Deep learning #Massachusetts Institute of Technology

AI helps find first new antibiotic in 60 years

Massachusetts Institute of Technology (MIT) researchers have used deep learning to identify a new class of antibiotic candidates that can kill methicillin-resistant Staphylococcus aureus (MRSA). The study represents more good news in the battle against antimicrobial resistance, as researchers from Harvard University and Roche also recently announced… Read More

#News #Trending News

Patient speaking to psychiatrist
#Depression #Major depressive disorder #Oncology #Phase II trial #Psychedelics #Sunstone Therapies

Psychedelic reduces depressive symptoms in cancer patients

Results from a Phase II clinical trial indicate that psilocybin may benefit individuals with cancer and major depression. In the study, trial participants treated with psilocybin not only experienced a lessening of depressive symptoms but also spoke highly of the therapy when interviewed at the end… Read More

#News #Trending News

The European Medicines Agency building
#CHMP #EU #European Medicines Agency #Gene therapy #Regulatory

New drug recommendations by the EU’s CHMP

The European Medicines Agency (EMA) human medicines committee (CHMP) made a number of key recommendations at its December 2023 meeting. Casgevy The committee recommended granting a conditional marketing authorisation for Casgevy (exagamglogene autotemcel), an advanced therapy medicinal product (ATMP) for the treatment of transfusion dependent beta-thalassemia and severe sickle cell… Read More

#News #Regulatory #Trending News

Breast cancer research
#Antibody drug conjugate (ADC) #Breast cancer #Cancer research #Clinical trials #Oncology

The latest advances in breast cancer therapy

A number of companies presented breakthrough data for their investigational breast cancer drugs at the San Antonio Breast Cancer Symposium. Antibody drug conjugate MBRC-101 MBrace Therapeutics presented preclinical data demonstrating the potential of its novel antibody drug conjugate MBRC-101 for the treatment of solid tumours including… Read More

#Cancer Research #News #Trending News

CAR-T therapy
#Blood cancer #CAR-T #Haematology #Kite Pharma #Oncology #Real world data

Real-world evidence supports use of CAR-T therapies in blood cancers

Real-world evidence from the French DESCAR-T registry has shown an overall response rate (ORR) of 76.9% and complete response rate (CR) of 57.7% in large B-cell lymphoma (LBCL) patients treated with axicabtagene ciloleucel (Yescarta). Axicabtagene ciloleucel was also associated with less than 5% grade ≥3 cytokine… Read More

#Cancer Research #News #Trending News